公开(公告)号：US08660817B2

公开(公告)日：2014-02-25

申请号：US12288099

申请日：2008-10-15

申请人： Tao Jiang ,  Xiaohua Xie

发明人： Tao Jiang ,  Xiaohua Xie

IPC分类号： G01F11/30

CPC分类号： G06F11/27

摘要： There is provided a hardware test and diagnosis system including a diagnostic computer and a cellular communication device. The cellular communication device includes a peripheral chipset on a circuit board and a cellular baseband controller on the circuit board, wherein the cellular baseband controller is configured to execute an agent software on the circuit board. The agent software is configured to communicate with the diagnostic computer, the agent software further configured to communicate with the peripheral chipset, and provide a virtual communication channel between the diagnostic computer and the peripheral chipset.

摘要翻译： 提供了包括诊断计算机和蜂窝通信设备的硬件测试和诊断系统。 蜂窝通信设备包括电路板上的外围芯片组和电路板上的蜂窝基带控制器，其中蜂窝基带控制器被配置为在电路板上执行代理软件。 代理软件被配置为与诊断计算机通信，代理软件还被配置为与外围芯片组通信，并且在诊断计算机和外围芯片组之间提供虚拟通信信道。

公开(公告)号：US20090157356A1

公开(公告)日：2009-06-18

申请号：US12288099

申请日：2008-10-15

申请人： Tao Jiang ,  Xiaohua Xie

发明人： Tao Jiang ,  Xiaohua Xie

IPC分类号： G06F15/00

CPC分类号： G06F11/27

摘要： There is provided a hardware test and diagnosis system comprising a diagnostic computer and a test device. The test device comprises a peripheral chipset and a baseband controller configured to execute an agent software. The agent software is configured to be coupled to the diagnostic computer, and the agent software is further configured to be coupled to the peripheral chipset of the test device. The agent software is further configured to provide a virtual channel between the diagnostic computer and the peripheral chipset. In one embodiment, the agent software comprises a driver configured for communication with the peripheral chipset, and is further configured to receive additional software from the diagnostic computer. In another embodiment, the agent software is further configured to be embedded in a boot code of the test device.

摘要翻译： 提供了包括诊断计算机和测试装置的硬件测试和诊断系统。 测试设备包括外围芯片组和被配置为执行代理软件的基带控制器。 代理软件被配置为耦合到诊断计算机，并且代理软件被进一步配置为耦合到测试设备的外围芯片组。 代理软件还被配置为在诊断计算机和外围芯片组之间提供虚拟通道。 在一个实施例中，代理软件包括被配置为与外围芯片组通信的驱动器，并且还被配置为从诊断计算机接收附加软件。 在另一个实施例中，代理软件还被配置为嵌入在测试设备的引导代码中。

公开(公告)号：USD946004S1

公开(公告)日：2022-03-15

申请号：US29796129

申请日：2021-06-22

申请人： Tao Jiang

设计人： Tao Jiang

公开(公告)号：US08592432B2

公开(公告)日：2013-11-26

申请号：US12936199

申请日：2009-04-03

申请人： Bei Chen ,  Tao Jiang ,  Thomas H. Marsilje ,  Pierre-Yves Michellys ,  Truc Ngoc Nguyen ,  Wei Pei ,  Baogen Wu ,  Zhaobo Gao ,  Yonghui Ge ,  Chen Huang ,  Yuncheng Li ,  Xuefeng Zhu

发明人： Bei Chen ,  Tao Jiang ,  Thomas H. Marsilje ,  Pierre-Yves Michellys ,  Truc Ngoc Nguyen ,  Wei Pei ,  Baogen Wu ,  Zhaobo Gao ,  Yonghui Ge ,  Chen Huang ,  Yuncheng Li ,  Xuefeng Zhu

IPC分类号： A61K31/506 ,  A61K31/5377 ,  C07D239/42 ,  C07D239/30 ,  C07D295/108 ,  C07D487/04 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04

CPC分类号： C07D239/48 ,  C07D403/12 ,  C07D403/14 ,  C07D487/04

摘要： The invention provides novel pyrimidine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, c-ros oncogene (ROS), insulin-like growth factor (IGF-1R), and/or insulin receptor (InsR) or a combination thereof.

摘要翻译： 本发明提供新颖的嘧啶衍生物及其药物组合物，以及使用这些化合物的方法。 例如，本发明的嘧啶衍生物可用于治疗，改善或预防对间变性淋巴瘤激酶（ALK）活性，c-ros致癌基因（ROS），胰岛素样生长因子（IGF-1R ）和/或胰岛素受体（InsR）或其组合。

公开(公告)号：US08524904B2

公开(公告)日：2013-09-03

申请号：US12630192

申请日：2009-12-03

申请人： Christopher W. Grote ,  Peter X. Wang ,  Tao Jiang ,  Gary L. Cantrell ,  Frank W. Moser ,  Catherine E. Thomasson

发明人： Christopher W. Grote ,  Peter X. Wang ,  Tao Jiang ,  Gary L. Cantrell ,  Frank W. Moser ,  Catherine E. Thomasson

IPC分类号： C07D489/08 ,  C07D489/02

CPC分类号： C07D489/02 ,  Y02P20/55

摘要： The present invention is directed to the preparation of 6-hydroxy morphinans having formula (II) or N-alkylated 6-hydroxy morphinans having formula (III).

摘要翻译： 本发明涉及具有式（II）的6-羟基吗啡烷或具有式（III）的N-烷基化的6-羟基吗啡喃的制备。

公开(公告)号：US20130131699A1

公开(公告)日：2013-05-23

申请号：US13679041

申请日：2012-11-16

申请人： Tao Jiang ,  Jian Q. Yao ,  Hali Wang ,  Timothy A. Hoeman ,  Ray Zubok ,  John Chernosky ,  Keith A. Roby

发明人： Tao Jiang ,  Jian Q. Yao ,  Hali Wang ,  Timothy A. Hoeman ,  Ray Zubok ,  John Chernosky ,  Keith A. Roby

IPC分类号： A61B17/68

CPC分类号： A61F2/0811 ,  A61B17/68 ,  A61F2002/0858 ,  A61F2002/0888 ,  A61F2250/0021 ,  A61F2250/0023 ,  A61F2250/0026 ,  A61L27/04 ,  A61L27/56

摘要： The present disclosure relates, in some aspects, to orthopaedic implants for securing soft tissue to bone and methods for using the same. One particular implant comprises a first exposed porous surface region, having pores for promoting bone ingrowth, and a second exposed porous surface, having pores for promoting soft tissue ingrowth. At least some of the pores of the first exposed porous surface region may be seeded with osteocytic factors and at least some of the pores of the second exposed porous surface region may be seeded with fibrocytic factors. Such orthopaedic implants can advantageously facilitate regeneration of the soft tissue to bone interface.

公开(公告)号：US20130005748A1

公开(公告)日：2013-01-03

申请号：US13610422

申请日：2012-09-11

申请人： Pierre-Yves Michellys ,  Wei Pei ,  Thomas H. Marsilje ,  Wenshuo Lu ,  Bei Chen ,  Tetsuo Uno ,  Yunho Jin ,  Tao Jiang

发明人： Pierre-Yves Michellys ,  Wei Pei ,  Thomas H. Marsilje ,  Wenshuo Lu ,  Bei Chen ,  Tetsuo Uno ,  Yunho Jin ,  Tao Jiang

IPC分类号： A61K31/519 ,  A61P31/00 ,  A61P35/00 ,  A61P37/06 ,  A61K31/52 ,  A61K31/517

CPC分类号： A61K31/506 ,  A61K31/5377 ,  A61K45/06 ,  C07D213/74 ,  C07D239/48 ,  C07D239/95 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D405/14 ,  C07D413/12 ,  C07D417/12 ,  C07D451/02 ,  C07D453/02 ,  C07D471/04 ,  C07D473/16 ,  C07D487/04 ,  C07D487/08

摘要： The invention provides novel pyrimidine and pyridine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine and pyridine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, focal adhesion kinase (FAK), zeta-chain-associated protein kinase 70 (ZAP-70), insulin-like growth factor (IGF-1R), or a combination thereof.

公开(公告)号：US08252928B2

公开(公告)日：2012-08-28

申请号：US12558646

申请日：2009-09-14

申请人： Peter X. Wang ,  Tao Jiang ,  David W. Berberich

发明人： Peter X. Wang ,  Tao Jiang ,  David W. Berberich

IPC分类号： C07D489/02 ,  C07D489/08

CPC分类号： C07D489/02 ,  C07D489/00

摘要： The present invention provides processes for the synthesis of five and six membered rings. In particular, the present invention provides processes for the synthesis of five and six membered rings in alkaloids.

摘要翻译： 本发明提供合成五元和六元环的方法。 特别地，本发明提供了合成生物碱中五元和六元环的方法。

公开(公告)号：US08202971B2

公开(公告)日：2012-06-19

申请号：US12499767

申请日：2009-07-08

申请人： Xiguang Chen ,  Jing Li ,  Xiaojie Cheng ,  Tao Jiang

发明人： Xiguang Chen ,  Jing Li ,  Xiaojie Cheng ,  Tao Jiang

IPC分类号： C08B37/08

CPC分类号： C08B37/003

摘要： A process for preparing compounds of chitosan saccharified with aminosugar, adopts chitosan derivatives, aminosugar derivatives and anhydride derivatives as raw materials to synthesize target products. The process comprises: covalently bonding an anhydride derivative as a bonding arm to an aminosugar derivative, so as to form a monosaccharide derivative having an end group of carboxyl; and then covalently bonding the monosaccharide derivative having an end group of carboxyl to a primary amino group of a chitosan derivative via the carboxyl, so as to form a compound of chitosan saccharified with aminosugar.

摘要翻译： 用氨基糖糖化糖壳化合物的方法，采用壳聚糖衍生物，氨基糖衍生物和酸酐衍生物为原料合成目标产物。 该方法包括：将作为结合臂的酸酐衍生物与氨基糖衍生物共价键合，形成具有羧基端基的单糖衍生物; 然后通过羧基将具有羧基末端基团的单糖衍生物共价键合到壳聚糖衍生物的伯氨基上，以形成用氨基糖糖化的壳聚糖化合物。

公开(公告)号：US20120134931A1

公开(公告)日：2012-05-31

申请号：US13384591

申请日：2010-07-15

申请人： Roger Tsien ,  Tood Aguilera ,  Emilia Olson ,  Tao Jiang ,  Quyen Nguyen

发明人： Roger Tsien ,  Tood Aguilera ,  Emilia Olson ,  Tao Jiang ,  Quyen Nguyen

IPC分类号： A61K49/06 ,  C07K9/00 ,  C07K7/02 ,  A61K49/00

CPC分类号： A61K47/64 ,  A61K47/595 ,  A61K47/60 ,  A61K47/62 ,  A61K47/6911 ,  A61K49/0032 ,  A61K49/0056 ,  C07K7/06

摘要： Disclosed herein, in certain embodiments, is a selective transport molecule with increased in vivo circulation. In some embodiments, a selective transport molecule disclosed herein has the formula (A-X-B-C)-M, wherein C is a cargo moiety; A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X is a linker; and M is a macromolecular carrier.

摘要翻译： 在某些实施方案中，本文公开了具有增加的体内循环的选择性转运分子。 在一些实施方案中，本文公开的选择性转运分子具有式（A-X-B-C）-M，其中C是货物部分; A是具有包含5至9个连续酸性氨基酸的序列的肽，其中所述氨基酸选自：天冬氨酸和谷氨酸; B是具有包含5至20个连续碱性氨基酸的序列的肽; X是一个连接子; M是大分子载体。